Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 3/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495295 | 0.80 | GRIK1 (0.39) | GRIK1GRIA2FFAR2HCRTR2PGR | |
| SCHEMBL3394385 | 0.79 | GRIK1 (0.37) | GRIK1GRIA2 | |
| SCHEMBL3303296 | 0.79 | HCRTR2 (0.35) | GRIK1GRIA2CTSSDDB1CRBN | |
| SCHEMBL9266331 | 0.75 | USP30 (0.36) | HCRTR2 | |
| SCHEMBL6488979 | 0.74 | FABP5 (0.40) | GRIK1GRIA2FFAR2PGRCYP2D6 | |
| SCHEMBL3395739 | 0.74 | GRIK1 (0.37) | GRIK1GRIA2FFAR2 | |
| SCHEMBL3391713 | 0.73 | GRIK1 (0.35) | GRIK1GRIA2CTSSCYP2C9POLB | |
| SCHEMBL6500575 | 0.72 | GRIK1 (0.39) | GRIK1GRIA2HCRTR2LMNAPGR | |
| SCHEMBL3392544 | 0.72 | GRIK1 (0.46) | GRIK1GRIA2CTSSLMNATDP1 | |
| SCHEMBL3391198 | 0.72 | GRIK1 (0.46) | GRIK1GRIA2CTSSLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2166003-A1 | Excitatory amino acid receptor antagonists | Eli Lilly & Company (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20060100237-A1 | Excitatory amino acid receptor antagonists | ARNOLD MACKLIN B | 2006-05-11 | — | — | US | disclosed |
| US-20040138254-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY | 2004-07-15 | — | — | US | disclosed |
| EP-1368032-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003024453-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138254-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, GRIN1 | GRIK1 8/4885GRIA2 14/4885CTSS 3012/4885 |
| US-20060100237-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, GRIN1 | GRIK1 8/4885GRIA2 14/4885CTSS 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.